1. Arbutus to Discontinue its P-Ia/Ib Clinical Study of AB-506 to Treat Patients with Chronic Hepatitis B Published: Oct 03, 2019 | Tags: Arbutus, Discontinue, P-Ia/Ib, Clinical Study, AB-506, Chronic Hepatitis […]readmore
Tags : Vertex
Shots: Ribometrix to get $20M up front including an equity investment in the company with $700M as development, regulatory and commercial milestones and royalties on sales on any product. Vertex […]readmore
1. Eisai And Biogen to Terminate Two P-III Clinical Studies of Elenbecestat (E2609) for Early Alzheimer’s Disease Published: Sept 13, 2019 | Tags: Eisai, Biogen, Terminate Two, P-III, Clinical Studies, Elenbecestat, […]readmore
Shots: The access agreement allows patients with eligible cystic fibrosis to access Orkambi and Symkevi (tezacaftor/ivacaftor) in combination with ivacaftor in Scotland Vertex will collect real-world data on the combination […]readmore
1.Roche’s Tecentriq + Chemotherapy Receives EC’s Approval as 1L Treatment for Extensive Stage Small Cell Lung Cancer Published: Sept 06, 2019 | Tags: Roche, Tecentriq, Chemotherapy, Receives, EC, Approval, Initial Treatment, […]readmore
Shots: Vertex acquires Semma Therapeutics, in all cash transaction making a total deal value $950M and Semma will operate as a subsidiary of Vertex. The transaction is expected to be […]readmore
Shots: Vertex signs a licensing agreement with CRISPR to develop & discover gene editing therapies for DMD and DM1. CRISPR to get $1B, as total deal value including $175M upfront, […]readmore
Shots: Kymera to receive $70M upfront including equity investment, >$1B as development, regulatory & commercial milestones for up to 6 therapies opted by Vertex, royalties on sales of products and […]readmore
Shots: The approval is based on P-III ARRIVAL study results assessing Kalydeco (ivacaftor) in 11 children with CF aged 6mos. to <12 mos. with 1/10 mutations in the CFTR gene […]readmore
Shots: The approval is based on P-III EVOLVE & EXPAND studies result assessing Symdeko vs PBO in 750 patients with CF having two copies of the F508del mutation or with […]readmore